Business Context and Reporting Period
This Form 8-K was filed by Bio-Rad Laboratories, Inc. on December 4, 2009, reporting events occurring on that date. The filing addresses a change in the composition of the Board of Directors and the resulting impact on the company's compliance with New York Stock Exchange (NYSE) listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance matters.
Material Changes
- Director Resignation: Mr. Ruediger Naumann-Etienne resigned as a member of the Board of Directors effective December 4, 2009. He was an independent director and served on the Audit and Compensation Committees.
- Listing Non-Compliance: The resignation reduced the number of independent directors on the Audit Committee to two, failing to meet the NYSE requirement of three independent directors under Section 303A.07(a) of the NYSE Listed Company Manual.
- Notification: The company notified the NYSE of this non-compliance on December 9, 2009.
Outlook, Risks, and Management Commentary
Management stated that Mr. Naumann-Etienne's resignation was not related to any disagreement with the Company's operations, policies, or practices. The company is actively seeking a replacement to serve on the Board and the Audit Committee and intends to regain compliance with NYSE requirements as soon as practicable. The primary risk identified is the temporary failure to satisfy the continued listing rule regarding audit committee composition.
Investor Verification Checklist
- Confirm the timeline for appointing a new independent director to the Audit Committee.
- Verify the company's status regarding NYSE compliance in subsequent filings.
- Review the composition of the Audit and Compensation Committees to ensure quorum and functionality during the vacancy.